Highlights of the important and the interesting from the world of healthcare:
Has the iPad been a disappointment for healthcare? Doubt any promise you hear about the iPad having a huge impact on the way healthcare is delivered–at least for now, writes Sandra Yin. Some of the breathless articles fawning over the device have overyped the reality of what medical professionals are really using the iPad to do now, she asserts. Of course, the device has only been around for six months and it’s often not wise to bet against Apple, so the verdict is hardly already in.
Starve the beast: In their effort to repeal health reform, Republicans hope to “de-fund” the law by denying the money necessary to enact the law’s various provisions. Of course, the plan would work much better if Republicans take control of both the House and Senate, which looks unlikely at this point.
Transforming Clinical Content with Ambient & Generative AI
Sheila Bond, MD, talked about the latest trends regarding integration of AI in healthcare.
AstraZeneca settlement: AstraZeneca will pay about $198 million to settle 17,500 lawsuits alleging its antipsychotic drug Seroquel causes diabetes in some users.
Tick tick boom: Many venture capitalists are sitting on ticking time bombs: end-of-life deadlines under which the funds must dispose of all their companies and wind down. The problem is many VCs are still holding onto the companies those funds invested in.
More of the same with NuPathe: Pennsylvania-based migraine drug developer NuPathe was just the latest biotech startup forced to cut its IPO price, settling on $10 after having targeted between $14 and $16. Only one biotech that’s gone public this year–Ironwood Pharmaceuticals–has seen its share price rise after trading has begun.
Putting the “me” in 23andMe: With doubts about the viability of the do-it-yourself, home genetic-testing market, is now a good time for 23andMe to be paying $4 million to one unidentified executive?
Integrating GLP-1s: How Berry Street is Redefining Nutrition Care
Richard Fu details the company's approach to nutrition therapy and strategy for patients using GLP-1s.
Photo from flickr user Yutaka Tsutano